Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Avadel Pharmaceuticals Plc ADR (AVDL)

Avadel Pharmaceuticals Plc ADR (AVDL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,097,672
  • Shares Outstanding, K 97,657
  • Annual Sales, $ 169,120 K
  • Annual Income, $ -48,830 K
  • EBIT $ 5 M
  • EBITDA $ 7 M
  • 60-Month Beta 1.30
  • Price/Sales 8.55
  • Price/Cash Flow N/A
  • Price/Book 21.28

Options Overview Details

View History
  • Implied Volatility 49.03% (-19.04%)
  • Historical Volatility 3.66%
  • IV Percentile 14%
  • IV Rank 29.63%
  • IV High 122.30% on 10/21/25
  • IV Low 18.18% on 10/24/25
  • Expected Move (DTE 2) 0.98 (4.55%)
  • Put/Call Vol Ratio 0.06
  • Today's Volume 1,030
  • Volume Avg (30-Day) 1,924
  • Put/Call OI Ratio 0.58
  • Today's Open Interest 91,468
  • Open Int (30-Day) 98,826
  • Expected Range 20.52 to 22.48

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.09
  • Number of Estimates 4
  • High Estimate 0.15
  • Low Estimate 0.03
  • Prior Year -0.05
  • Growth Rate Est. (year over year) +280.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.35 +0.68%
on 12/16/25
21.68 -0.83%
on 12/22/25
+0.14 (+0.66%)
since 12/12/25
3-Month
14.31 +50.24%
on 10/15/25
23.57 -8.78%
on 11/14/25
+7.13 (+49.62%)
since 10/14/25
52-Week
6.38 +236.99%
on 04/09/25
23.57 -8.78%
on 11/14/25
+13.45 (+167.08%)
since 01/14/25

Most Recent Stories

More News
Avadel Pharmaceuticals Announces that Avadel Shareholders Approve the Proposed Acquisition by Alkermes

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION....

AVDL : 21.50 (+0.09%)
Avadel Pharmaceuticals Announces Completion of Enrollment in Phase 3 REVITALYZ™ Trial in Idiopathic Hypersomnia

- Data expected in Q2 2026 - DUBLIN, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives,...

AVDL : 21.50 (+0.09%)
Avadel Pharmaceuticals Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avadel Pharmaceuticals plc - AVDL

NEW YORK and NEW ORLEANS , Dec. 12, 2025 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC ("KSF") are investigating...

AVDL : 21.50 (+0.09%)
ALKS : 30.62 (+5.04%)
Announcement relating to despatch of Rule 15 proposal

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION....

AVDL : 21.50 (+0.09%)
ALKS : 30.62 (+5.04%)
Announcement relating to despatch of Definitive Proxy Statement and details of Scheme Meeting and Extraordinary General Meeting

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION....

AVDL : 21.50 (+0.09%)
Announcement relating to convening of Scheme Meeting and Extraordinary General Meeting

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION....

AVDL : 21.50 (+0.09%)
Halper Sadeh LLC Encourages SEMR, AVDL, CADE, DENN Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

CADE : 43.64 (+0.97%)
SEMR : 11.88 (-0.08%)
AVDL : 21.50 (+0.09%)
DENN : 6.25 (unch)
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-DENN, ELST, AVDL, and CADE

NEW YORK , Nov. 19, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for...

CADE : 43.64 (+0.97%)
AVDL : 21.50 (+0.09%)
ELST : 0.0150 (-40.00%)
DENN : 6.25 (unch)
Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION...

AVDL : 21.50 (+0.09%)
ALKS : 30.62 (+5.04%)
Avadel Board of Directors Declares Lundbeck Proposal a “Company Superior Proposal”

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR...

AVDL : 21.50 (+0.09%)
ALKS : 30.62 (+5.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Avadel Pharmaceuticals plc is a specialty pharmaceutical company. Its product pipeline consists of hospital and paediatrics. Hospital segment provides Bloxiverz(R), Vazculep(R) and Akovaz(TM). Paediatrics segment provides Karbinal (TM) ER, AcipHex(R) Sprinkle and Flexichamber(TM). The company operates...

See More

Key Turning Points

3rd Resistance Point 21.69
2nd Resistance Point 21.65
1st Resistance Point 21.57
Last Price 21.50
1st Support Level 21.45
2nd Support Level 21.41
3rd Support Level 21.33

See More

52-Week High 23.57
Last Price 21.50
Fibonacci 61.8% 17.00
Fibonacci 50% 14.98
Fibonacci 38.2% 12.95
52-Week Low 6.38

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar